Clinical Trial

A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 13, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer (TNBC).
Trial Details
NCT Number NCT06685796
Lead Sponsor BeBetter Med Inc
Conditions Advanced Triple-Negative Breast Cancer
Enrollment 120 participants
Start Date 2023-04-12
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-13